Jennison Associates LLC Has $48.38 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Jennison Associates LLC increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,346,952 shares of the company's stock after purchasing an additional 19,730 shares during the quarter. Jennison Associates LLC owned approximately 1.34% of Dyne Therapeutics worth $48,383,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DYN. Sei Investments Co. acquired a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $693,000. Russell Investments Group Ltd. lifted its holdings in Dyne Therapeutics by 1.4% in the 1st quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company's stock worth $2,894,000 after purchasing an additional 1,447 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Dyne Therapeutics by 44.6% in the 1st quarter. ProShare Advisors LLC now owns 16,307 shares of the company's stock worth $463,000 after purchasing an additional 5,028 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. Finally, Ameritas Investment Partners Inc. lifted its holdings in Dyne Therapeutics by 28.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company's stock worth $167,000 after purchasing an additional 1,291 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Insider Transactions at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the company's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. This represents a 1.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of the company's stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the completion of the transaction, the director now owns 15,962 shares in the company, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,257 shares of company stock worth $6,193,718 in the last ninety days. Insiders own 20.77% of the company's stock.

Dyne Therapeutics Trading Down 0.1 %

Shares of Dyne Therapeutics stock traded down $0.02 during trading on Friday, reaching $29.71. The stock had a trading volume of 661,340 shares, compared to its average volume of 1,482,551. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -8.37 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52 week low of $10.12 and a 52 week high of $47.45. The stock has a fifty day moving average price of $32.25 and a two-hundred day moving average price of $35.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DYN. Oppenheimer restated an "outperform" rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Piper Sandler reaffirmed an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Morgan Stanley boosted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the company an "overweight" rating in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.